Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Hybridoma Technology01:31

Hybridoma Technology

17.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K
Antibody Structure and Classes01:25

Antibody Structure and Classes

9.5K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
9.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.

EMBO molecular medicine·2026
Same author

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Blood neoplasia·2026
Same author

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report.

Frontiers in immunology·2026
Same author

Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from <i>in vitro</i> assays.

Frontiers in immunology·2026
Same author

Colonic spatial single-cell proteomics and murine models link mitochondrial dysfunction to dimeric IgA-secreting plasma cell deficiency in Crohn's disease.

Nature communications·2026

Related Experiment Video

Updated: Feb 20, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K

Antibody Isotypes for Tumor Immunotherapy.

Anna Kretschmer1, Ralf Schwanbeck1, Thomas Valerius1

  • 1Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts-University, Kiel, Germany.

Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie
|October 27, 2017
PubMed
Summary

Exploring antibody isotypes beyond IgG1, such as IgA, IgE, and IgM, is crucial for developing novel immunotherapies. Optimizing isotype selection enhances therapeutic success in diverse clinical applications.

Keywords:
CancerImmune responseImmunoglobulin isotypesImmunotherapy

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.7K
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

7.7K

Related Experiment Videos

Last Updated: Feb 20, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.7K
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

7.7K

Area of Science:

  • Immunology
  • Biotechnology
  • Pharmacology

Background:

  • Therapeutic antibodies predominantly utilize the human IgG1 isotype, despite evolutionary diversity.
  • Other antibody isotypes (IgG, IgA, IgE, IgM) possess unique structures and functions.
  • Current antibody development shows a bias towards IgG1, limiting therapeutic potential.

Purpose of the Study:

  • To review the potential advantages of non-IgG1 antibody isotypes for therapeutic applications.
  • To highlight the importance of isotype selection for optimizing antibody-based therapies.
  • To explore the strategic value of investigating underutilized antibody isotypes.

Main Methods:

  • Review of existing literature on antibody isotype structure and function.
  • Analysis of factors influencing therapeutic antibody efficacy (antigen, epitope, mode of action, pharmacokinetics, biopharmaceutical considerations).
  • Discussion of IgG, IgA, IgE, and IgM isotypes in the context of immunotherapy.

Main Results:

  • IgG1 is the dominant isotype in approved therapeutic antibodies.
  • Alternative isotypes offer potential benefits for specific therapeutic indications.
  • Isotype selection is critical for maximizing therapeutic success.

Conclusions:

  • Further research into non-IgG1 antibody isotypes is warranted.
  • Strategic selection of antibody isotypes can differentiate therapies in a crowded market.
  • Exploring IgA, IgE, and IgM isotypes may unlock new immunotherapy opportunities.